Ready to Improve Your Biomarker Intelligence?

TALK TO A BIOMARKER STRATEGIST
Posts From the monthly archives: "March 2016"

We usually send company updates at the end of the year, but since we’ve accomplished so much in the past 5 months we had to share some of the highlights with you.  We’ve made major data coverage strides in our flagship product, BiomarkerBase: 10,165 new Lab Developed Tests (most complete known coverage…(Read More)

This week we took a look at FDA-cleared and approved IVDs for oncology, and grouped them based on whether they measure proteins or nucleic acids.  Protein-based tests have historically been the dominant type used in the clinic, but this is changing rapidly.  Based on our just-completed forecast, nucleic acid-based test approvals…(Read More)

BIOMARKERBASE NEW DATA ANNOUNCEMENT At Amplion we are always adding more data from both known and new sources. Today we are happy to announce that we now have coverage of EU-based clinical trials. EU clinical trial coverage gives BiomarkerBase users another information source to make strategic product portfolio decisions, provide top-notch industry analysis…(Read More)

This week’s chart is pulled from the same analysis we did last week.  Last week we introduced the concept of a biomarker quadrant showing Hot, Common, Emerging, and Under-performing biomarkers by usage since first introduced.  This week we want to simplify things  in our Chart of the Week.  This chart represents the distribution…(Read More)

This week’s Chart of the Week is an interesting one.  We will most likely have a follow up after further analysis of the data from BiomarkerBase.  Basically, the chart shows the total commercial usage of a biomarker by company count since the biomarkers first clinical usage, by years.  This analysis allows us to categorize…(Read More)

We are interested in how biomarkers are used in all aspects of healthcare.  Today Amplion is focused on the supporting the research side of healthcare with our product BiomarkerBase, helping diagnostic, pharma and life science companies make strategic decisions involving the use of biomarkers. Most of these decisions involve pharmaceutical and diagnostic product development, but…(Read More)